ArticleDrug design, development and therapy2020
Phoenixin 14 Inhibits High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Experimental Mice.
Article in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06891586 (Investigation of the Relationship Between Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of the Relationship Between Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Renoprotective Potential of Nateglinide in an Acute Kidney Injury Model.International journal of molecular sciences · 2026Article
- Comparative renoprotective effects of phoenixin-14, a novel peptide, and dexamethasone in LPS-induced sepsis: targeting inflammation, oxidative stress, and apoptosis.Apoptosis : an international journal on programmed cell death · 2026Article
- Phoenixin-14 ameliorates ovarian morphology in a DHEA-induced rat model of PCOS.Reproduction & fertility · 2026Article
- Protective Effects of Phoenixin-14 Administration Against Renal Ischemia/Reperfusion Injury in Rats.Journal of biochemical and molecular toxicology · 2025Article
- Alterations in Glutathione Redox Homeostasis in Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review.Antioxidants (Basel, Switzerland) · 2024Review
- Examining the Potential Applicability of Orexigenic and Anorexigenic Peptides in Veterinary Medicine for the Management of Obesity in Companion Animals.Current issues in molecular biology · 2024Review
- Plasma extracellular vesicle microRNAs reflecting the therapeutic effect of the CBP/β-catenin inhibitor PRI-724 in patients with liver cirrhosis.Scientific reports · 2024Article
- A systematic scoping review of the multifaceted role of phoenixin in metabolism: insights fromFrontiers in endocrinology · 2024Article
- The Levels of Phoenixin-14 and Phoenixin-20 in Patients with Type 2 Diabetes Mellitus.Endocrine, metabolic & immune disorders drug targets · 2024Article
- Dietary ribose supplementation improves flesh quality through purine metabolism in gibel carp (Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2023Article
- Dihydroartemisinin ameliorates the liver steatosis in metabolic associated fatty liver disease mice by attenuating the inflammation and oxidative stress and promoting autophagy.Acta cirurgica brasileira · 2023Article
- Linking mitochondrial dynamics and fertility: promoting fertility by phoenixin through modulation of ovarian expression of GnRH receptor and mitochondrial dynamics proteins DRP-1 and Mfn-2.Pflugers Archiv : European journal of physiology · 2022Article
- Phoenixin-14 alters transcriptome and steroid profiles in female green-spotted puffer (Dichotomyctere nigroviridis).Scientific reports · 2022Article
- The Regulation of Phoenixin: A Fascinating Multidimensional Peptide.Journal of the Endocrine Society · 2022Review
- Regulation and physiological functions of phoenixin.Frontiers in molecular biosciences · 2022Review
- Investigation of serum phoenixin levels in patients with hypertension.Revista da Associacao Medica Brasileira (1992) · 2022Article
- Di'ao Xinxuekang Capsule Improves the Anti-Atherosclerotic Effect of Atorvastatin by Downregulating the SREBP2/PCSK9 Signalling Pathway.Frontiers in pharmacology · 2022Article
- Review
- Phoenixin: More than Reproductive Peptide.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases. The development of NAFLD is closely associated with hepatic lipotoxicity, inflammation, and oxidative stress. The new concept of NAFLD treatment is to seek molecular control of lipid metabolism and hepatic redox hemostasis. Phoenixin is a newly identified neuropeptide with pleiotropic effects. This study investigated the effects of phoenixin 14 against high-fat diet (HFD)-induced NAFLD in mice. MATERIALS AND
methodsFor this study, we used HFD-induced NAFLD mice models to analyze the effect of phonenixin14. The mice were fed on HFD and normal diet and also given phoenixin 14 (100 ng/g body weight) by gastrogavage for 10 weeks. The peripheral blood samples were collected for biochemical assays. The liver tissues were examined for HFD-induced tissue fibrosis, lipid deposition and oxidative activity including SOD, GSH, and MDA. The liver tissues were analyzed for the inflammatory cytokines and oxidative stress pathway genes.
resultsThe results indicate that phoenixin 14 significantly ameliorated HFD-induced obesity and fatty liver. The biochemical analysis of blood samples revealed that phoenixin 14 ameliorated HFD-induced elevated circulating alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, and triglyceride levels, suggesting that phoenixin 14 has a protective role in liver function and lipid metabolism. Hematoxylin-eosin (HE) and Oil Red O staining of the liver showed that phoenixin 14 alleviated HFD-induced tissue damage and lipid deposition in the liver. Furthermore, the mice administered with phoenixin 14 had increased hepatic SOD activity, increased production of GSH and reduced MDA activity, as well as reduced production of TNF-α and IL-6 suggesting that phoenixin 14 exerts beneficial effects against inflammation and ROS. The findings suggest an explanation of how mechanistically phoenixin 14 ameliorated HFD-induced reduced activation of the SIRT1/AMPK and NRF2/HO-1 pathways.
conclusionCollectively, this study revealed that phoenixin 14 exerts a protective effect in experimental NAFLD mice. Phoenixin could be of the interest in preventive modulation of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.